18449940. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS simplified abstract (Massachusetts Institute of Technology)
DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS
Organization Name
Massachusetts Institute of Technology
Inventor(s)
Feng Zhang of Cambridge MA (US)
Silvana Konermann of Zurich (CH)
James Dahlman of Cambridge MA (US)
Omar Abudayyeh of Cambridge MA (US)
DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18449940 titled 'DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS
Simplified Explanation
The invention provides systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formulation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular, the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
- Structural information on the Cas protein of the CRISPR-Cas system
- Generation of modified components of the CRISPR complex
- Vectors and vector systems encoding components of a CRISPR complex
- Methods for directing CRISPR complex formulation in eukaryotic cells
- Utilization of the CRISPR-Cas system
Potential Applications
The technology can be applied in gene editing, genetic engineering, and biotechnology research.
Problems Solved
The technology provides a more efficient and precise method for altering gene expression and gene products.
Benefits
The technology allows for targeted gene editing, potentially leading to advancements in medical treatments and genetic research.
Potential Commercial Applications
The technology could be used in pharmaceutical research, biotech companies, and genetic engineering firms.
Possible Prior Art
Prior art may include earlier methods of gene editing and genetic modification techniques.
Unanswered Questions
How does this technology compare to other gene editing methods?
The article does not provide a direct comparison to other gene editing methods such as TALENs or zinc finger nucleases.
What are the limitations of this technology in practical applications?
The article does not address any potential limitations or challenges in implementing this technology in real-world scenarios.
Original Abstract Submitted
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are stmctural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formulation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.